Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Plans For Enough H1N1 Flu Shots For 25 Million

This article was originally published in PharmAsia News

Executive Summary

Japan's plan to switch in mid-July from producing vaccines against seasonal flu viruses to producing H1N1 vaccines is expected to enable authorities to have enough vaccine on hand to protect 25 million people. The Health Ministry released data that said H1N1 vaccinations could begin in Japan as early as October. The H1N1 supply would be in addition to the stockpile of seasonal flu vaccines, which the ministry said are capable of protecting 40 million people. In January, the government expects to begin producing a vaccine against avian flu. (Click here for more - a subscription may be required

You may also be interested in...



Illegal Drug/Device Products Among Seizures By US/Indian Operation

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

Pfizer Launches Biosimilar Trastuzumab In US

Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.

Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

UsernamePublicRestriction

Register

SC071866

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel